Who owns Nurix Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of NRIX from SEC Form 13F filings across 235 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 235 institutions disclosed 119.8M shares of Nurix Therapeutics, Inc. worth $2.84B — about 107.3% of shares outstanding; the largest disclosed holder is BlackRock, Inc.. Source: SEC Form 13F filings, parsed by EvidInvest.
235
13F holders
$2.84B
value, 2026 filers
107.3%
of shares outstanding (119.8M sh)
48
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of NRIX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 8.8M | $208.7M | 0.0% | 7.9% | +0.4% |
| 2 | Redmile Group, LLC | 7.9M | $187.3M | 13.7% | 7.1% | +93.9% |
| 3 | Vestal Point Capital, LP | 7.0M | $166.6M | 4.3% | 6.3% | -12.7% |
| 4 | Deep Track Capital, LP | 6.0M | $142.3M | 2.3% | 5.4% | -22.4% |
| 5 | PERCEPTIVE ADVISORS LLC | 5.4M | $127.4M | 2.2% | 4.8% | +24.3% |
| 6 | MORGAN STANLEY | 5.2M | $124.4M | 0.0% | 4.7% | +10.2% |
| 7 | Rubric Capital Management LP | 5.0M | $117.8M | 1.1% | 4.5% | -31.3% |
| 8 | FMR LLC | 4.7M | $111.0M | 0.0% | 4.2% | -14.7% |
| 9 | BAKER BROS. ADVISORS LP | 4.7M | $110.5M | 0.5% | 4.2% | 0.0% |
| 10 | PRICE T ROWE ASSOCIATES INC /MD/ | 4.6M | $108.4M | 0.0% | 4.1% | -15.9% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 4.5M | $106.8M | 0.0% | 4% | +0.2% |
| 12 | STATE STREET CORP | 4.4M | $105.0M | 0.0% | 4% | -5.3% |
| 13 | GENERAL ATLANTIC, L.P. | 3.0M | $71.9M | 2.9% | 2.7% | 0.0% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 2.5M | $59.7M | 0.0% | 2.3% | -0.8% |
| 15 | ARK Investment Management LLC | 1.9M | $43.9M | 0.3% | 1.7% | +3.3% |
| 16 | Capital World Investors | 1.8M | $42.4M | 0.0% | 1.6% | 0.0% |
| 17 | Trails Edge Capital Partners, LP | 1.6M | $37.3M | 5.4% | 1.4% | 0.0% |
| 18 | DIMENSIONAL FUND ADVISORS LP | 1.3M | $31.2M | 0.0% | 1.2% | -8.1% |
| 19 | EVENTIDE ASSET MANAGEMENT, LLC | 1.3M | $30.8M | 0.4% | 1.2% | 0.0% |
| 20 | GOLDMAN SACHS GROUP INC | 1.3M | $30.4M | 0.0% | 1.1% | +57.5% |
| 21 | ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 1.3M | $30.4M | 0.0% | 1.1% | +168.4% |
| 22 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.3M | $29.9M | 0.0% | 1.1% | -14.9% |
| 23 | BANK OF AMERICA CORP /DE/ | 1.3M | $29.6M | 0.0% | 1.1% | +48.5% |
| 24 | Kynam Capital Management, LP | 1.2M | $28.3M | 1.6% | 1.1% | 0.0% |
| 25 | Pictet Asset Management Holding SA | 1.1M | $26.8M | 0.0% | 1% | -51.9% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.